Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iomai has received approval from the Department of Health and Human Services to expand its program to develop an immunostimulant adjuvant patch, for use with an injected H5N1 influenza vaccine.
Subscribe to our email newsletter
This decision was based upon positive clinical data generated in a 500-subject, Phase I/II study recently completed by Iomai. Guided by data from this study, Iomai will begin a Phase II dose-ranging study designed to identify the optimum dose of antigen and adjuvant that can be used in a one-dose or two-dose regimen to enhance the immune response to a H5N1 influenza vaccine.
Stanley Erck, president and CEO of Iomai, said: “The Iomai immunostimulant patch has the potential to change how we react to an influenza pandemic, and we will move ahead quickly with the development of this technology. Based on the data from this new Phase II study, Iomai and HHS will evaluate whether to proceed next with a pivotal Phase III trial.”